Related Experiment Videos
In vivo selective modulation of tissue glutathione in a rat mammary carcinoma model
1Department of Oncology, Lady Davis Research Institute, Sir Mortimer B. Davis-Jewish General Hospital, Montreal, Quebec, Canada.
Abstract:
Glutathione (GSH) is known to play a role in cellular sensitivity to some chemotherapeutic agents and to radiation. Depletion of cellular GSH has been demonstrated to result in enhanced toxicity of these drugs, and this approach is being explored in the clinic as a form of biochemical modulation, using the drug buthionine sulfoximine (BSO). The fact that some drug-resistant cell lines have increased glutathione levels, and that enhancing GSH concentrations in animal tissues protects against a variety of xenobiotic agents, suggest a different potential approach to improving anti-cancer therapy. We have examined the efficacy of the cysteine "pro-drug" L-2-oxothiazolidine-4-carboxylate (OTZ) at enhancing normal tissue versus tumor GSH. Animals were treated with OTZ or BSO, and the concentrations of GSH in normal tissues and tumor were measured. We found that the presence of the tumor itself decreased bone marrow GSH, but that OTZ significantly increased it in this setting. Interestingly, OTZ administration significantly depleted tumor GSH levels to the same level as did BSO. OTZ could offer a selective biochemical modulation of GSH.
Insights
L-2-oxothiazolidine-4-carboxylate (OTZ) selectively modulates glutathione (GSH) levels. This approach enhances normal tissue GSH while depleting tumor GSH, offering a novel strategy for cancer therapy.
Area of Science:
- Biochemistry
- Oncology
- Pharmacology
Background:
- Glutathione (GSH) influences cellular sensitivity to chemotherapy and radiation.
- Depleting GSH enhances drug toxicity, a strategy explored clinically with buthionine sulfoximine (BSO).
- Elevated GSH in resistant cell lines and protective effects in animal tissues suggest GSH modulation for cancer therapy.
Purpose of the Study:
- To investigate the efficacy of L-2-oxothiazolidine-4-carboxylate (OTZ) in modulating normal tissue versus tumor glutathione (GSH) levels.
- To explore OTZ as a potential selective biochemical modulator for cancer treatment.
Main Methods:
- Animals were treated with either OTZ or BSO.
- Glutathione (GSH) concentrations were measured in normal tissues (bone marrow) and tumors.
- Comparative analysis of GSH levels between OTZ, BSO, and control groups.
Main Results:
- Tumor presence decreased bone marrow GSH levels.
- OTZ administration significantly increased bone marrow GSH in tumor-bearing animals.
- OTZ treatment effectively depleted tumor GSH levels, comparable to BSO.
- OTZ demonstrated selective modulation of GSH in normal versus tumor tissues.
Conclusions:
- OTZ selectively enhances normal tissue glutathione (GSH) while depleting tumor GSH.
- This selective modulation by OTZ presents a promising approach for biochemical modulation in cancer therapy.
- OTZ offers a potential alternative to BSO for targeted GSH modulation.